How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage

被引:49
作者
Goodnough, Lawrence Tim [1 ,2 ]
Shander, Aryeh [3 ]
机构
[1] Stanford Univ, Med Ctr, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA
[3] Englewood Hosp & Med Ctr, Dept Anesthesiol & Crit Care, Englewood, NJ USA
关键词
PROTHROMBIN COMPLEX CONCENTRATE; ACTIVATED FACTOR-VII; FRESH-FROZEN PLASMA; RECOMBINANT FACTOR VIIA; CENTRAL-NERVOUS-SYSTEM; INTERNATIONAL NORMALIZED RATIO; ORAL ANTICOAGULANT REVERSAL; INTRAVENOUS VITAMIN-K; INTRACRANIAL HEMORRHAGE; URGENT REVERSAL;
D O I
10.1182/blood-2010-11-316075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intracerebral hemorrhage in patients with warfarin-associated coagulopathy is an increasingly common life-threatening condition that requires emergent management. The evolution of therapeutic options in this setting, as well as recently published guidelines, has resulted in some heterogeneity in recommendations by professional societies. This heterogeneity can be attributed to lack of evidence-based support for plasma therapy; the variability in availability of prothrombin complex concentrates; the variability in the coagulation factor levels and contents of prothrombin complex concentrates; ambiguity about the optimal dose and route of administration of vitamin K; and the lack of standardized clinical care pathways, particularly in community hospitals, for the management of these critical care patients. In this review, we summarize the relevant literature about these controversies and present recommendations for management of patients with warfarin-associated coagulopathy and intracerebral hemorrhage.(Blood. 2011;117(23):6091-6099)
引用
收藏
页码:6091 / 6099
页数:9
相关论文
共 105 条
[31]   Recombinant factor VIIa for rapid reversat of warfarin, anticoagulation in acute intracranial hemorrhage [J].
Freeman, WD ;
Brott, TG ;
Barrett, KM ;
Castillo, PR ;
Deen, HG ;
Czervionke, LF ;
Meschia, JF .
MAYO CLINIC PROCEEDINGS, 2004, 79 (12) :1495-1500
[32]   Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy:: a double-blind placebo-controlled andomised trial [J].
Friederich, PW ;
Herny, CP ;
Messelink, EJ ;
Geerdink, MG ;
Keller, T ;
Kurth, KH ;
Büller, HR ;
Levi, M .
LANCET, 2003, 361 (9353) :201-205
[33]   Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage [J].
Goldstein, JN ;
Thomas, SH ;
Frontiero, V ;
Joseph, A ;
Engel, C ;
Snider, R ;
Smith, EE ;
Greenberg, SM ;
Rosand, J .
STROKE, 2006, 37 (01) :151-155
[34]   Warfarin reversal in anticoagulant-associated intracerebral hemorrhage [J].
Goldstein, Joshua N. ;
Rosand, Jonathan ;
Schwamm, Lee H. .
NEUROCRITICAL CARE, 2008, 9 (02) :277-283
[35]   Transfusion medicine service policies for recombinant factor VIIa administration [J].
Goodnough, LT ;
Lublin, DM ;
Zhang, L ;
Despotis, G ;
Eby, C .
TRANSFUSION, 2004, 44 (09) :1325-1331
[36]   Warfarin reversal [J].
Hanley, JP .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (11) :1132-1139
[37]   Production and composition of prothrombin complex concentrates: Correlation between composition and therapeutic efficiency [J].
Hellstern, P .
THROMBOSIS RESEARCH, 1999, 95 (04) :S7-S12
[38]   Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose [J].
Holland, Lorne ;
Warkentin, Theodore E. ;
Refaai, Majed ;
Crowther, Mark A. ;
Johnston, Marilyn A. ;
Sarode, Ravindra .
TRANSFUSION, 2009, 49 (06) :1171-1177
[39]   Toward rational fresh frozen plasma transfusion - The effect of plasma transfusion on coagulation test results [J].
Holland, Lorne L. ;
Brooks, Jay P. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (01) :133-139
[40]   A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization [J].
Hung, A ;
Singh, S ;
Tait, RC .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :537-539